RHYTHM PHARMACEUTICALS, INC.
In the published model solve dated 2026-Q2, anchored at $110.57, RHYTHM PHARMACEUTICALS, INC. (RYTM) is priced for today's economics sustained for ~19.5 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
- At about $96.79 (June 28, 2026) the stock trades near 33x trailing revenue with the company still running a deep operating loss, gross margin near 90%. The price is set against sales, not profit, and it implies the business eventually reaches a roughly 36% operating margin and grows at its self-funding ceiling for close to nineteen years. - No valuation family reaches the price. Asset methods anchor on a $1.81 book value per share, the forward-growth methods land in the $50s, and the peer mult
Is RYTM overvalued? See what's priced in →
274 institutional managers reported holding RYTM in 13F filings for the quarter ended 2026-03-31. 53 opened new positions that quarter. Held by Vanguard Group, BlackRock, PRIMECAP Management, among others. On the short side, 8.0M shares were sold short as of the 2026-06-15 count, about 12% of shares outstanding (11.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
RYTM's share count grew 35.4% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at RYTM over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
RYTM's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-02 | +36.3% | -12.1% |
| 2023-11-09 | +1.2% | +54.1% |
| 2024-03-01 | -1.5% | +0.1% |
| 2024-05-08 | -11.3% | +14.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
RYTM's latest 8-K filings: 2026-08-04 (items 2.02, 7.01, 8.01, 9.01); 2026-06-25 (items 5.07); 2026-06-15 (items 7.01, 8.01, 9.01); 2026-05-05 (items 2.02, 9.01); 2026-04-03 (items 5.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.